Redhill Biopharma Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K reports on the Annual General Meeting of Shareholders held on May 2, 2018. Redhill Biopharma Ltd. is a foreign private issuer based in Tel Aviv, Israel, filing under Form 20-F.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance actions and shareholder resolutions.
Material Changes and Corporate Actions
Shareholders approved all seven proposed resolutions at the May 2, 2018 meeting:
- Appointment of Kesselman & Kesselman (PricewaterhouseCoopers International) as independent auditors for 2018.
- Increase in authorized share capital by 300 million ordinary shares.
- Re-election of Ofer Tsimchi, Kenneth Reed, and Eric Swenden to the Board of Directors for three-year terms ending in 2021.
- Amendment to the 2010 Award Plan to increase the maximum number of issuable shares.
- Grant of 500,000 options to CEO Dror Ben-Asher.
- Extension of options granted to CEO Dror Ben-Asher.
- Extension of options granted to non-executive director Ofer Tsimchi.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, or contingencies. The document serves as a record of shareholder approvals and is incorporated by reference into existing Registration Statements (Forms S-8 and F-3).
Key Facts for Investor Verification
- Verification of the 300 million share capital increase and its potential dilution impact.
- Confirmation of the specific terms for the new 500,000 options granted to the CEO.
- Review of the amended 2010 Award Plan to understand the new maximum share issuance limits.
- Confirmation of the re-elected directors' tenure through 2021.